Protocol Ledger

NCT04310930 · Phase II/III · RECRUITING

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Interventional Phase II/III clinical trial protocol NCT04310930 sponsored by The University of Queensland in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-03-02 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04310930
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04310930
Protocol FieldVerified Registry Value
NCT IdentifierNCT04310930
Consolidated Lead SponsorThe University of Queensland
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2020-03-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04310930
Hospital Research SiteLocationSite Profile
Queensland Children's HospitalSouth Brisbane, AustraliaOpen Hospital Dossier ->
Princess Alexandra HospitalWoolloongabba, AustraliaOpen Hospital Dossier ->
Austin HospitalHeidelberg, AustraliaOpen Hospital Dossier ->
Royal Melbourne HospitalParkville, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI